 Unclear if tissue diagnosis in poor PS lung cancer patients alters outcomes  Tissue diagnosis did not affect treatment or survival in most PS 3 or 4 patients  Those receiving treatment requiring tissue diagnosis had improved survival  Aids decision whether to pursue tissue in PS 3 or 4 patients.
Abstract
Introduction 25% of patients with lung cancer have performance status 3 or 4. A pragmatic approach to investigative procedures is often adopted based on the risks and benefits in these patients and whether tissue diagnosis is necessary for anticipated future treatment. This cohort study investigated factors influencing a clinician's decision to pursue a tissue diagnosis in patients with lung cancer and performance status 3 and 4 and to examine the association of tissue diagnosis with subsequent management and survival.
Methods
All patients with lung cancer diagnosed in North Glasgow from 2009 to 2012 were prospectively recorded in a registry. We investigated the relationships between achieving a tissue diagnosis, treatment and survival.
Results
Of 2493 patients diagnosed with lung cancer, 490 patients (20%) were PS 3 and 122 patients (5%) were PS 4. Tissue diagnosis was attempted in 60% and 35% patients with PS 3 and PS 4 respectively. Younger age, better performance status and having stage 4 disease were independently associated with a diagnostic procedure being performed.
Only 5% of patients with poor performance status received treatment conventionally requiring a tissue diagnosis. Age, stage and performance status were independent predictors of mortality. Achieving a tissue diagnosis was not associated with mortality. Receiving treatment requiring tissue diagnosis is associated with survival benefit.
Conclusions
The majority of patients with poor fitness undergo a diagnostic procedure which does not influence further treatment or affect survival. However, the cohort of patients who do undergo therapy determined by tissue diagnosis have improved survival.
Introduction
Lung cancer is still the most common cause of cancer death in the UK,(1) and whilst the overall age-standardised incidence of lung cancer in the UK is slowly decreasing,(2) the age-standardised incidence of lung cancer in women over the age indicators across 7 domains which are income, employment, health, education, skills and training, housing, geographic access and crime.
Statistical analysis
Summary statistics were described as number of subjects and percentages for all categorical variables. Logistic regression analyses were performed to estimate the odds ratio and 95% confidence intervals (95%CI) for factors related to having a tissue diagnosis. Cox Proportional hazards regression was performed to estimate hazard ratios and 95%CI for factors associated with all-cause mortality. For both logistic regression and cox regression, initial univariate analysis was performed using relevant variables and those with an association yielding a p-value of less than 0.1 were put into the final models. SPSS version 22.0 was used for analysis and the graphs generated using GraphPad Prism 6.0.
Results
There were 2493 patients diagnosed with lung cancer between 2009 and 2012. The mean age was 71 with an even gender split (male sex 49%; Table 1 ). The majority of patients had stage 3B or 4 lung cancer at diagnosis (64%). The median follow up period was 43 months (minimum 17, maximum 70) and 98% of patients were followed up to death or 2 years.
Performance status was documented in 93% of patients. Pathological tissue diagnosis was confirmed in 96% of PS 0 and 1 patients and 80% in PS 2. There were 490 patients (20%) with PS 3 and 122 patients (5%) with PS 4 (Table 2) . These less fit patients were older (all patients mean age 71; PS 3 and 4 mean age 76) and had a female preponderance (all patient male sex 49%; PS 3 and 4 45%). Tissue diagnosis was attempted in 60% and 35% and was successful in 50% and 27% of patients with PS 3 and PS 4 respectively. 62% of PS3 and 83% of PS4 patients had stage 4 lung cancer. 9% of PS3 and 7% of PS 4 patients had more than one procedure.
Logistic regression was performed to assess whether specific patient characteristics influenced clinicians' decisions regarding attempting tissue diagnosis (Table 3) . As expected, younger age and better performance status were independently associated with a diagnostic procedure being performed. Additionally, patients with either stage 1 or stage 4 disease were more likely to undergo a diagnostic procedure than those with stage 2 or 3.
Subsequent treatment of lung cancer is shown in Figure 2B ). The majority of these patients had small cell lung cancer (Table 5 ).
Discussion
Almost all randomised controlled trials evaluating therapy in patients with lung cancer recruit patients of good performance status (PS). ( In a cohort of patients with a poor PS, we have looked at which patients undergo a diagnostic procedure and its influence on treatment and mortality. In our large cohort, 25% of patients had poor PS. 60% and 35% of patients with PS 3 and 4 underwent a diagnostic procedure respectively. We found that younger age and better performance status were independently associated with the performance of a diagnostic procedure, There are a number of reasons for choosing to obtain a tissue diagnosis in patients with lung cancer. Firstly it is used to confirm the diagnosis. However, two-thirds of patients of poor performance status have radiologically confirmed stage 4 lung cancer and thus pathological confirmation is less likely to be essential to secure a diagnosis.
In some patients, tissue diagnosis is obtained as part of a therapeutic procedure to improve symptoms, such as aspiration of a pleural effusion. Pleural aspiration is less invasive than bronchoscopy or lung biopsy. The higher proportional rate of pleural aspirate as a diagnostic procedure in our PS 3 and 4 patients may reflect this (Table   2 ).
An alternative reason for performing a diagnostic procedure is to direct therapy.
Historically, patients with PS 3 and 4 would not be considered for systemic treatment. inhibitors that are better tolerated with a lesser side-effect profile, but at present this only represents a small minority of patients.
We recognise that rates of treatment with chemotherapy in patients with PS 3 and 4 vary between centres, and this may be higher in some specialist centres treating highly selected patients in comparison to our unselected cohort. All patients in this study were discussed at a MDT in the presence of three consultant lung cancer oncologists and, along with performance status, other factors such as co-morbidities, patient's wishes, expectation and deprivation level may have been relevant in the decision not to give systemic treatment.
Limitations
This cohort of patients is from the North Glasgow area. While a significant proportion of the patients are of lower socioeconomic status, there is a reasonable distribution.
This distribution will be similar to many other industrial towns and cities with high prevalence of cigarette smoking and similar rates of lung cancer, and thus the findings are relevant and applicable to other areas of the UK and overseas.
It is possible that the patients who underwent treatment directed by their tissue diagnosis had been misclassified as PS3. While a useful measure of general fitness, this scale is subjective. Indeed in a study of 100 consecutive cancer patients from Denmark, overall there was only moderate agreement between three oncologists recording performance status (overall Kappa 0.55). (18) However, in our cohort, performance status is independently associated with mortality and thus likely to be accurate in the majority of cases.
Conclusion
Thus in this cohort, many patients of performance status 4 undergo a diagnostic procedure which does not influence further treatment or affect survival. However, some patients of performance status 3 received treatment determined by tissue diagnosis and this is associated with improved survival. Therefore, patients with performance status 3 who would be considered for chemotherapy, including biological or targeted therapy, should be offered a tissue diagnosis.
Clinical Practice Points
 It is currently not known whether a tissue diagnosis in patients with lung cancer and poor performance status (PS) affects subsequent management and survival.
 The majority of patients with PS 3 or 4 underwent a diagnostic procedure which did not affect further treatment or affect survival.
 However, those patients who did have treatment requiring tissue diagnosis had improved survival -the majority of these had small cell lung cancer.
 This manuscript will aid clinicians in making decisions regarding whether or not to obtain histological confirmation in the 25% of patients who are performance status 3 or 4.
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